Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Finding a New Cause for Cardiac Injury in Kidney Disease
Disease Discoveries

Finding a New Cause for Cardiac Injury in Kidney Disease

By Nora DunneNov 12, 2015
Share
Facebook Twitter Email
Wolf-Amaral
Myles Wolf, MD, MMSc, director of the Center for Translational Metabolism and Health, and Ansel Amaral, MD, PhD, a second-year resident in the Physician-Scientist Training Program and the Department of Medicine, were two authors of the study.

A recent study co-authored by Northwestern Medicine scientists demonstrates a new molecular mechanism that may underlie left ventricular hypertrophy, a pattern of cardiac injury in which the heart’s main pumping chamber thickens and stiffens, eventually leading to heart failure.

The findings could lead to important applications for patients with chronic kidney disease, 75 percent of whom will develop left ventricular hypertrophy by the time they reach end-stage kidney disease.

“Left ventricular hypertrophy disproportionately affects the chronic kidney disease population due to a unique set of pathological factors,” said co-first author Ansel Amaral, MD, PhD, a second-year resident in the Physician-Scientist Training Program and the Department of Medicine. “This study elucidated a molecular pathway that will provide a new target for pharmacological intervention in the near future.”

Working with scientists at the University of Miami, Amaral discovered that activating a cell surface protein called fibroblast growth factor receptor 4 (FGFR4) on heart muscle cells can induce left ventricular hypertrophy in animal models with and without kidney disease. The findings were published in Cell Metabolism.

“This suggests a new avenue for trying to prevent heart disease in settings where FGFR4 is excessively activated,” said Myles Wolf, MD, MMSc, director of the Center for Translational Metabolism and Health, who helped lead the research.

The scientists defined the cell-signaling pathway that mediates the hypertrophic growth of heart muscle cells in response to FGFR4 activation, and they showed that blocking FGFR4 with an antibody can help prevent the cardiac injury. Taken together, the study’s results suggest a cause of left ventricular hypertrophy that was not known before.

The findings also support previous research reported by Dr. Wolf’s group, which linked left ventricular hypertrophy to high circulating levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which binds to FGFR4 in the heart.

Dr. Wolf, the Margaret Gray Morton Professor of Medicine in the Division of Nephrology, will continue to investigate the mechanisms behind left ventricular hypertrophy, and the role excess dietary phosphate plays in the disease’s development, through a Northwestern research center funded by the American Heart Association.

Valentin David, PhD, and Aline Martin, PhD, both research assistant professors of Medicine in Nephrology, also co-authored the recent paper.

The study was supported by Stifterverband für die Deutsche Wissenschaft and Simon-Claussen-Stiftung grant H1405409999915626, Deutsche Forschungs Gemeinschaft grants GR 4228/1-1 and SFB656 C7, Roche Pharmaceuticals, the Max Planck Society, Daiichi-Sankyo, State of Florida grant 3KN05 and the Florida Heart Research Institute, the Starr Foundation, the American Heart Association, the American Society of Nephrology, U3 Pharma GmbH and National Institutes of Health grants F30DK091057, F31DK10236101, F31DK09566101, R01DK090316, R01DK104753, K01AG040468, R01HL110737, R01HL094849, R01HL107110, R01HL084275, R01DK076116, K24DK093723 and R01HL128714.

Cardiology Research
Share. Facebook Twitter Email

Related Posts

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
pride7
pride6
pride5
pride4
pride3
pride2
pride1
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.